KW-6356

What it is & what research shows

Study example available

KW-6356 is a selective adenosine A2A receptor antagonist/inverse agonist investigated in Parkinson’s disease. The research below distinguishes observed findings from interpretation. [1.1]

Selected human research: 168 patients in a randomized, double-blind trial: oral KW-6356 3 mg or 6 mg once daily versus placebo for 12 weeks. The primary motor-examination score improved by 5.37 points with 3 mg, 4.76 with 6 mg and 3.14 with placebo. Constipation occurred in 7.3% and 10.3% of the active-dose groups. This is disease-specific motor-function research, not a healthy-person focus or motivation trial. The abstract does not demonstrate disease modification. This is disease-specific motor-function research, not a healthy-person focus or motivation trial. The abstract does not demonstrate disease modification. [2.1]

Studied methods, not dosing advice. Selected evidence, not a complete literature review or formal quality appraisal.

Sources & reading scope

[1.1] KW-6356 monotherapy in early untreated Parkinson’s diseaseHuman · primary publication abstract
[2.1] KW-6356 monotherapy in early untreated Parkinson’s diseaseAbstract-based reading note

Study-summary coverage

No completed study summaries are linked to this compound page yet. This is a coverage gap on PED Evidence, not evidence that human studies or other research do not exist.

Filter, save and compare KW-6356 studies →

Selected study reading notes

Source-linked summaries with studied methods. These are separate from the automated summary counts above and are not formal quality appraisals.

Human2023

KW-6356: what does this study show?

168 patients in a randomized, double-blind trial: oral KW-6356 3 mg or 6 mg once daily versus placebo for 12 weeks.

Demonstrated findings

The primary motor-examination score improved by 5.37 points with 3 mg, 4.76 with 6 mg and 3.14 with placebo. Constipation occurred in 7.3% and 10.3% of the active-dose groups.

Limitations & adverse findings

This is disease-specific motor-function research, not a healthy-person focus or motivation trial. The abstract does not demonstrate disease modification.

What might this mean? · interpretation

These findings apply to the population and methods described above.

What might this mean, and what would change the interpretation?

This is disease-specific motor-function research, not a healthy-person focus or motivation trial. The abstract does not demonstrate disease modification.

What would clarify this: Independent replication with clinically meaningful outcomes and longer safety follow-up.

Findings reviewed · abstract

Checked Sep 23, 2026 against the linked abstract. This reading note is not a formal risk-of-bias appraisal.

KW-6356 monotherapy in early untreated Parkinson’s disease

More about KW-6356: identity, safety & reference details

Small moleculeBrain & cognition

Primary research area: Neurological & cognitive research
Regulatory status: See compound-specific sources
Evidence level: Human research · indication-specific
Primary mechanism: See the source-linked compound overview

Reference profile available · Coverage varies by section

Also known as KW6356

What has been observed?

Selected source-linked reading notes, not the complete literature or a pooled conclusion.

Human · Abstract reviewed

KW-6356: what does this study show?

168 patients in a randomized, double-blind trial: oral KW-6356 3 mg or 6 mg once daily versus placebo for 12 weeks.

The primary motor-examination score improved by 5.37 points with 3 mg, 4.76 with 6 mg and 3.14 with placebo. Constipation occurred in 7.3% and 10.3% of the active-dose groups.

Limits & adverse findings: This is disease-specific motor-function research, not a healthy-person focus or motivation trial. The abstract does not demonstrate disease modification. This is disease-specific motor-function research, not a healthy-person focus or motivation trial. The abstract does not demonstrate disease modification.

Open primary source · Read interpretation separately

Explore outcomes for this compound

Uses & research: The research below distinguishes observed findings from interpretation. [1]
Known half-life: No source-verified value in this profile yet. A treatment schedule or duration of an effect is not a drug half-life.
Half-life describes how quickly the measured drug concentration falls by half. It does not set a dosing interval.
Evidence & important limits: This is disease-specific motor-function research, not a healthy-person focus or motivation trial. The abstract does not demonstrate disease modification. [1]

Safety & evidence boundaries

Source-specific information, not a personal safety clearance or monitoring plan.

This is disease-specific motor-function research, not a healthy-person focus or motivation trial. The abstract does not demonstrate disease modification.

KW-6356 monotherapy in early untreated Parkinson’s disease

Human study: This is disease-specific motor-function research, not a healthy-person focus or motivation trial. The abstract does not demonstrate disease modification. Source

Explore safety questions by system

These are literature filters, not claims that this compound causes each effect. A keyword match is not a confirmed adverse reaction.

Heart, blood pressure & lipids Liver injury Kidney function Glucose effects Reproductive & endocrine effects Mood & sleep Adverse effects & interactions

Interactions, rare harms, long-term effects and reversibility require separate evidence. Do not infer they are absent when the sources here do not address them.

Identity, names & formulations

Canonical compound: KW-6356 · kw6356

Searchable names: KW6356

Names share a parent research page. Different esters, salts, routes and brands are not assumed to have the same half-life, indication or exposure.

Combination evidence stays attached to the studied combination. It is not automatically assigned to each ingredient.

Understand the evidence types

Read the model and design first, then the population, outcome and limitations. These categories describe evidence, not a best-compound ranking.

Randomized human trials: Compare assigned interventions. Randomization does not by itself establish low bias or relevance to every population.
Controlled human studies: Use a comparison group; allocation and confounding still matter.
Prospective human research: Follows participants forward. It may be observational or interventional, so this is not a separate quality grade.
Observational human research: Describes associations. Confounding can explain differences.
Case reports and series: Useful for unusual events and safety signals, not reliable rates or effect sizes.
Animal research: Can test biology and function in a living model. Human exposure, benefit and safety remain separate questions.
Cell and tissue research: Tests responses in a preparation, including human-derived cells. It is not a human participant trial.
Mechanistic and computational evidence: Helps explain or predict a pathway; predictions need experimental and clinical testing.
Anecdotal reports: Self-reported experiences can generate questions. Product identity, selection bias and other interventions may be uncontrolled.

Systematic reviews synthesize studies and depend on their quality. Preprint status and abstract versus full-paper reading are separate labels. Citation popularity measures attention, not reliability. A study summary is not a formal quality appraisal.

Sources for this profile

1. KW-6356 monotherapy in early untreated Parkinson’s disease Human · primary publication abstract

Reference facts checked 2026-09-23. Source scope is listed above; this is not a formal quality appraisal. See each label for full prescribing information.

Browse all studies

Research outcomeResearch model

Study model describes the source. Confidence depends on methods, replication, population and outcome.

Loading compound research…